Compare Novartis AG (NVS) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Carparts.Com Inc — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Carparts.Com Inc trades at $8.59 (market cap $66.42M). The key difference: Novartis AG is far larger — about 4043.5× Carparts.Com Inc's market cap, and Novartis AG pays a 3.31% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Carparts.Com Inc for 45 Days on average.
| NVS | PRTS | |
|---|---|---|
Market Cap | $268.57B | $66.42M |
Volume | 1,532,573 | 40,287 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $10.00 |
52-Week Low | $121.80 | $3.88 |
Typical Hold Time | 82 Days | 45 Days |
Enterprise Value | $309.89B | $79.39M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
CarParts.com (PRTS) trades at $8.695, up 0.99% with a bullish technical signal. The company shows improving quarterly earnings performance, beating expectations in recent quarters, though remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, but net losses are narrowing. Analyst sentiment is positive with 60% buy ratings, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential recovery as earnings improve and losses narrow, supported by analyst optimism. Key risks include persistent negative cash flow, competitive pressures in auto parts e-commerce, and execution challenges in returning to profitability. The stock offers speculative upside if the company can sustain its earnings beat trend and stabilize revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
